Evidence of a role for RANKL in the development of myeloma bone disease.
Curr Opin Pharmacol
; 4(4): 340-6, 2004 Aug.
Article
en En
| MEDLINE
| ID: mdl-15251126
ABSTRACT
Multiple myeloma is associated with the development of a devastating bone disease mediated by increased osteoclastic activity. The ligand for receptor activator of nuclear factor-kappaB (RANKL) plays a critical role in normal osteoclast biology and is abnormally regulated in myeloma. Targeting this system with recombinant decoy receptor, osteoprotegerin, or soluble forms of the receptor activator of nuclear factor-kappaB is able to prevent myeloma bone disease in pre-clinical models. Intriguingly, inhibiting osteoclast formation and bone resorption, and altering the bone marrow microenvironment, results in an indirect anti-myeloma effect.
Buscar en Google
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Resorción Ósea
/
Glicoproteínas de Membrana
/
Proteínas Portadoras
/
Mieloma Múltiple
Tipo de estudio:
Prognostic_studies
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Curr Opin Pharmacol
Asunto de la revista:
FARMACOLOGIA
Año:
2004
Tipo del documento:
Article
País de afiliación:
Reino Unido